Table 1.
Clinicopathologic characteristics of RET altered breast cancers
| Characteristics | All breast cancer cases | RET altered cases | RET activating rearrangement | RET uncharacterized rearrangement | RET missense mutation | RET amplification |
|---|---|---|---|---|---|---|
| Number of cases (n) | 9693 | 121 | 8 | 8 | 25 | 81 |
| Median age (range), years | 54 (20–88) | 56 (31–85) | 61.5 (54–66) | 60 (48–69) | 52 (33–71) | 54 (28–85) |
| Median tumor mutational burden (range), mutations/Mb | 3.6 (0–251.4) | 4.5 (0–36.6) | 5.2 (0.9–7.2) | 4.5 (1.8–17.1) | 3.6 (0–36.6) | 4.5 (0–16.2) |
| Breast (n) as site of origin of sequenced sample | 3859 | 49 | 4 | 4 | 7 | 34 |
| Sequenced sample from a metastatic site (n) | 5834 | 72 | 4 | 4 | 40 | 47 |
| ER positive | NA | 34 (34.7%) | 2 (25%) | 2 (25%) | 15 (71.4%) | 16 (25%) |
| ER negative | NA | 64 (65.3%) | 5 (75%) | 5 (75%) | 6 (28.6%) | 48 (75%) |
| ER unknown | 8221 | 23 | 1 | 1 | 4 | 17 |
| ERBB2 amplified | 1019 (10.5%) | 22 (18.2%) | 1 (12.5%) | 1 (12.5%) | 5 (20.0%) | 15 (18.5%) |
| ERBB2 nonamplified | 8674 (89.5%) | 99 (81.8%) | 7 (87.5%) | 7 (87.5%) | 20 (80.0%) | 66 (81.5%) |
Italics represent gene encoding RET, ERBB2
ER estrogen receptor status measured by routine clinical immunohistochemistry, ERBB2 gene amplification status by genomic profiling; ER and ERBB2 represented as numbers (%), NA not applicable, Mb megabase